Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Oncology

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDH429PMID 15520061
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA).

  2004cited by this paper
• Epothilones: mechanism of action and biologic activity.

  2004cited by this paper
• A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC).

  2004cited by this paper
• Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.

  2003cited by this paper
• Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy

  2003cited by this paper
• Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.

  2002cited by this paper
• Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

  2002cited by this paper
• A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.

  2001cited by this paper
• The efficacy of endocrine combination therapy with aminoglutethimide and hydrocortisone in metastatic prostatic cancer refractory to standard endocrine therapies

  2001cited by this paper
• Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

  2001cited by this paper
• Phase II study of vinorelbine in patients with androgen-independent prostate cancer.

  2001cited by this paper
• Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

  2000cited by this paper
• Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma

  2000cited by this paper
• Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.

  2000cited by this paper
• Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

  2000cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.

  1999cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

  1999cited by this paper
• Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.

  1999cited by this paper
• Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.

  1999cited by this paper
• Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer.

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• Hormone-refractory (D3) prostate cancer: refining the concept.

  1995cited by this paper
• Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer.

  1988cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper
• The measurement of observer agreement for categorical data.

  1977influential reference

• Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review

  2025cites this paper
• Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• Androgen receptor signalling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration sensitive prostate cancer.

  2021cites this paper
• A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer

  2020cites this paper
• Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

  2019cites this paper
• LA CHIMIOTHERAPIE DE L’ADENOCARCINOME PROSTATIQUE : ETAT DE L’ART EN 2019

  2019influential citation
• Chemotherapy of Prostatic Adenocarcinoma : State of the Art 2019

  2019cites this paper
• CANCER THERAPY

  2018cites this paper
• Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

  2018cites this paper
• Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis.

  2018influential citation
• Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials

  2017cites this paper
• Prevalence of Measurable Disease in Metastatic Castration‐resistant Prostate Cancer

  2017cites this paper
• Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer.

  2016cites this paper
• Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.

  2016cites this paper
• Incidence and Correlates of Fatigue in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review.

  2016cites this paper
• [Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].

  2015cites this paper
• Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors

  2014cites this paper
• Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.

  2014cites this paper
• Chemotherapy for Castration Resistant Metastatic Prostate Cancer

  2014cites this paper
• End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review.

  2014cites this paper
• Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer

  2013cites this paper
• Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

  2012cites this paper
• [Prostate cancer and chemotherapy: standards care and perspectives].

  2012cites this paper
• Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

  2012cites this paper
• Chimiothérapies cytotoxiques et cancer de la prostate : standards et perspectives

  2012cites this paper
• Hormone-Refractory Prostate Cancer

  2012cites this paper
• Current management of prostate cancer: dilemmas and trials.

  2012cites this paper
• [Treatment of the patient with castration-resistant biochemical progression of prostate cancer].

  2012cites this paper
• Quality of life with advanced metastatic prostate cancer.

  2012cites this paper
• Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?

  2011cites this paper
• Cisplatin and TRAIL enhance breast cancer stem cell death.

  2011cites this paper
• New Strategies for Medical Management of Castration-Resistant Prostate Cancer

  2011cites this paper
• Clinical Trial Design for Testing the Stem Cell Model for the Prevention and Treatment of Cancer

  2011cites this paper
• Second‐line therapy for castrate‐resistant prostate cancer: A literature review

  2011cites this paper
• The Mechanism of Androgen Deprivation and the Androgen Receptor

  2010cites this paper
• Targeting breast cancer stem cells

  2010cites this paper
• Evolution of Docetaxel-Based Therapy for Metastatic Castrate-Resistant Prostate Cancer

  2010cites this paper
• Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer

  2010cites this paper
• Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide.

  2010cites this paper
• Targeting breast cancer stem cells.

  2010cites this paper
• Phase II study of paclitaxel and vinorelbine (Pacl‐Vin) in hormone‐refractory metastatic prostate cancer: double tubulin targeting

  2010cites this paper
• Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review.

  2010cites this paper
• High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment

  2009cites this paper
• Uro-Onkologie – Update 2009

  2009cites this paper
• Therapeutic implications of the cancer stem cell hypothesis.

  2009cites this paper
• Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

  2009cites this paper
• Novel secondary hormonal therapy in advanced prostate cancer: an update

  2009cites this paper
• Cytotoxic compounds in the treatment of castration-resistant prostate cancer.

  2009cites this paper
• Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means?

  2009influential citation
• Radiation therapy combined with hormone treatment for primary prostate cancer. Effects of radiation dose escalations and assessment of side effects

  2009cites this paper
• The Role of Chemotherapy in the Treatment of Bone Metastases

  2009cites this paper
• Kombinierte Chemotherapie und regionale Tiefenhyperthermie eines hormonrefraktären, ossär und hepatisch metastasierenden Prostatakarzinoms in der 5. Therapielinie

  2009cites this paper
• Chimiothérapie du cancer de la prostate

  2008cites this paper
• Le traitement des cancers de la prostate hormonorésistants

  2008cites this paper
• Oral Vinorelbine as First Line Chemotherapy in Unfit Elderly Patients with Hormone-Refractory Prostate Cancer

  2008cites this paper
• ANTI-ADHESION evolves to a promising therapeutic concept in oncology.

  2008cites this paper
• Cell Signaling Modifiers in Prostate Cancer

  2008cites this paper
• [Chemotherapy for prostate cancer].

  2008cites this paper
• Chemotherapie beim Prostatakarzinom

  2008cites this paper
• Management of metastatic prostate cancer: the crucial role of geriatric assessment

  2008cites this paper
• Medical approach to advanced prostate cancer in older patients

  2008cites this paper
• Chemotherapy for hormone-resistant prostate cancer: Where are we today?

  2007cites this paper
• Das hormonrefraktäre Prostatakarzinom – eine internistische Herausforderung

  2007cites this paper
• Hormone-refractory prostate cancer: choosing the appropriate treatment option.

  2007cites this paper
• Current indications for chemotherapy in prostate cancer patients.

  2007cites this paper
• [The hormone refractory prostate cancer - a challenge for the internal specialist].

  2007cites this paper
• Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?

  2007cites this paper
• Hormone-refractory prostate cancer: where are we going?

  2007cites this paper
• Development of abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor as a secondary hormonal therapy in prostate cancer

  2007cites this paper
• Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer

  2007cites this paper
• Chemotherapy for the treatment of hormone‐refractory prostate cancer

  2007cites this paper
• Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.

  2007cites this paper
• Metastasiertes hormonrefraktäres Prostatakarzinom

  2007cites this paper
• Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel

  2007cites this paper
• A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.

  2007cites this paper
• Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.

  2006cites this paper
• [Geriatric urology -- tumour diseases].

  2006cites this paper
• Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.

  2006cites this paper
• Strategies to eliminate cancer stem cells: clinical implications.

  2006cites this paper
• Chemotherapy for hormone-refractory prostate cancer.

  2006cites this paper
• The changing pattern of management for hormone-refractory, metastatic prostate cancer

  2006cites this paper
• Geriatrische Urologie - Tumorerkrankungen

  2006cites this paper
• Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

  2006influential citation
• KISS: the 2006 Annals of Oncology prizes

  2006cites this paper
• The paradox of response and survival in cancer therapeutics.

  2006cites this paper
• Geriatrische Urologie - Tumorerkrankungen

  2006cites this paper
• Interleukin-31: a new cytokine involved in inflammation of the skin.

  2006cites this paper
• Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?

  2005cites this paper
• Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

  2005cites this paper
• [Prostate cancer: update].

  2005cites this paper
• [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer].

  2005cites this paper
• Chemotherapy for metastatic disease: current status.

  2005cites this paper
• Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.

  2005cites this paper
• Management of advanced prostate cancer after first-line chemotherapy.

  2005cites this paper
• [Update of the treatment of advanced prostate cancer and management of its complications].

  2005cites this paper
• Actualización del tratamiento del cáncer de próstata avanzado y de sus complicaciones

  2005cites this paper
• Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer

  2005cites this paper
• Chemotherapy for patients with hormone-refractory prostate cancer.

  2004cites this paper
• Highlights from the 29th European Society for Medical Oncology Congress: Vienna, Austria, October 29 through November 2, 2004.

  2004cites this paper